Zobrazeno 1 - 10
of 252
pro vyhledávání: '"Claudio Zamagni"'
Autor:
Fabio Canino, Monica Barbolini, Ugo De Giorgi, Tommaso Fontana, Valeria Gaspari, Caterina Gianni, Lorenzo Gianni, Antonio Maestri, Santino Minichillo, Luca Moscetti, Antonella Mura, Stefania Vittoria Luisa Nicoletti, Claudia Omarini, Rachele Pagani, Samanta Sarti, Angela Toss, Claudio Zamagni, Riccardo Cuoghi Costantini, Federica Caggia, Giuseppina Antonelli, Federica Baglio, Lorenzo Belluzzi, Giulio Martinelli, Salvatore Natalizio, Ornella Ponzoni, Massimo Dominici, Federico Piacentini
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-18 (2024)
Abstract Background The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown to increase the pathological complete response (pCR) rate, with
Externí odkaz:
https://doaj.org/article/1ac6fc48a61047d696aefc89f35bee02
Autor:
Martina Ferioli, Anna M. Perrone, Milly Buwenge, Alessandra Arcelli, Maria Vadala’, Bruno Fionda, Maria C. Malato, Pierandrea De Iaco, Claudio Zamagni, Silvia Cammelli, Luca Tagliaferri, Alessio G. Morganti
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9895-9905 (2023)
Radiotherapy (RT) and electrochemotherapy (ECT) are established local treatments for cancer. While effective, both therapies have limitations, especially in treating bulky and poorly oxygenated tumors. ECT has emerged as a promising palliative treatm
Externí odkaz:
https://doaj.org/article/47063de65d664538b7a8d2c71af85275
Autor:
Stefano Ferretti, Priscilla Sassoli de Bianchi, Debora Canuti, Cinzia Campari, Laura Cortesi, Valentina Arcangeli, Elena Barbieri, Cecilia D’Aloia, Rita Danesi, Pierandrea De Iaco, Margherita De Lillo, Laura Lombardo, Gabriella Moretti, Antonino Musolino, Dante Palli, Caterina Palmonari, Mila Ravegnani, Alfredo Tafà, Alessandra Tononi, Daniela Turchetti, Claudio Zamagni, Valentina Zampiga, Lauro Bucchi, the HBOC Study Group
Publikováno v:
Methods and Protocols, Vol 7, Iss 4, p 63 (2024)
Hereditary breast/ovarian cancer (HBOC) syndrome is caused by the inheritance of monoallelic germline BRCA1/2 gene mutations. If BRCA1/2 mutation carriers are identified before the disease develops, effective actions against HBOC can be taken, includ
Externí odkaz:
https://doaj.org/article/45a7886160724011a27d7da7efcaef86
Autor:
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Externí odkaz:
https://doaj.org/article/dcf619c78545464a823c5d3ef4cc8cc3
Autor:
Benedetta Pellegrino, Luisa Carbognin, Emilio Bria, Alberto Zambelli, Filippo Montemurro, Elena Fiorio, Claudio Zamagni, Nicoletta Campanini, Michele Tognetto, Gabriele Missale, Antonino Musolino, Stefania Gori, Giuseppe Maglietta, Chiara Tommasi, Olga Serra, Elisabetta Cretella, Massimo Ambroggi, Antonio Frassoldati, Giancarlo Bisagni, Chiara Casarini, Antonella Mura, Lorenzo Gianni, Renata Todeschini, Enrico Maria Silini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background It is possible to induce immunomodulation in HER2-positive breast cancer (BC) by modifying the route of administration of trastuzumab.Methods In this multicenter randomized phase II trial, all enrolled patients (pts) with T2–T4d HER2-pos
Externí odkaz:
https://doaj.org/article/cb245d7c7a6b4364ba2d9bf6da750467
Autor:
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionEndometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%–15% of women with EC are diagnosed with advanced-stage disease, resulting in a repor
Externí odkaz:
https://doaj.org/article/f5bb38ac79f64befb91e18a43fc5f3ed
Autor:
Domenica Lorusso, Romano Danesi, Laura Deborah Locati, Gianluca Masi, Ugo De Giorgi, Angiolo Gadducci, Sandro Pignata, Roberto Sabbatini, Antonella Savarese, Giorgio Valabrega, Claudio Zamagni, Nicoletta Colombo
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/01160f11902f41b39a39a31497957622
Autor:
Dario de Biase, Thais Maloberti, Angelo Gianluca Corradini, Francesca Rosini, Marco Grillini, Martina Ruscelli, Sara Coluccelli, Annalisa Altimari, Elisa Gruppioni, Viviana Sanza, Daniela Turchetti, Andrea Galuppi, Martina Ferioli, Susanna Giunchi, Giulia Dondi, Marco Tesei, Gloria Ravegnini, Francesca Abbati, Daniela Rubino, Claudio Zamagni, Pierandrea De Iaco, Donatella Santini, Claudio Ceccarelli, Anna Myriam Perrone, Giovanni Tallini, Antonio De Leo
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionThe European Society of Gynecologic Oncology/European Society of Radiation Therapy and Oncology/European Society of Pathology (ESGO/ESTRO/ESP) committee recently proposed a new risk stratification system for endometrial carcinoma (EC) pat
Externí odkaz:
https://doaj.org/article/636a6ccb0216497ab54dc7a9845d8fa7
Autor:
Luca Gianni, Marco Colleoni, Giancarlo Bisagni, Mauro Mansutti, Claudio Zamagni, Lucia Del Mastro, Stefania Zambelli, Giampaolo Bianchini, Antonio Frassoldati, Ilaria Maffeis, Pinuccia Valagussa, Giuseppe Viale
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The crosstalk between estrogen and HER2 receptors and cell-cycle regulation sustains resistance to endocrine therapy of HER2- and hormone receptor-positive breast cancer. We earlier reported that women with HER2 and ER-positive breast cancer
Externí odkaz:
https://doaj.org/article/e542c52ccbb647d2bea1317628f87e5c
Autor:
Domenica Lorusso, Romano Danesi, Laura Deborah Locati, Gianluca Masi, Ugo De Giorgi, Angiolo Gadducci, Sandro Pignata, Roberto Sabbatini, Antonella Savarese, Giorgio Valabrega, Claudio Zamagni, Nicoletta Colombo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionThe combination of lenvatinib plus pembrolizumab demonstrated a relevant clinical benefit in patients with endometrial carcinoma. The safety profile was consistent with the established profiles of each drug in monotherapy, with the most f
Externí odkaz:
https://doaj.org/article/3326d4a85d0b488b9f8013eaaad98244